GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (FRA:CSJ) » Definitions » LT-Debt-to-Total-Asset

CSL (FRA:CSJ) LT-Debt-to-Total-Asset : 0.30 (As of Jun. 2024)


View and export this data going back to 2009. Start your Free Trial

What is CSL LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. CSL's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.30.

CSL's long-term debt to total assets ratio declined from Jun. 2023 (0.31) to Jun. 2024 (0.30). It may suggest that CSL is progressively becoming less dependent on debt to grow their business.


CSL LT-Debt-to-Total-Asset Historical Data

The historical data trend for CSL's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL LT-Debt-to-Total-Asset Chart

CSL Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 0.29 0.18 0.31 0.30

CSL Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.31 0.31 0.29 0.30

CSL LT-Debt-to-Total-Asset Calculation

CSL's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (A: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Jun. 2024 )/Total Assets (A: Jun. 2024 )
=10441.031/35322.438
=0.30

CSL's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )/Total Assets (Q: Jun. 2024 )
=10441.031/35322.438
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CSL  (FRA:CSJ) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


CSL LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of CSL's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


CSL Business Description

Industry
Address
655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

CSL Headlines

No Headlines